At Emerging Markets, we like to keep our eye on new potentially disruptive sectors. We found Cannabis in 2010 and everyone laughed at us. Fast forward to today Cannabis has turned into a massive industry. We see psychedelics as the next Cannabis. Peter Thiel has backed several companies in this space, as the saying goes "follow the money". Enter SILO, a company new to market who has assembled a very impressive team. As the saying goes, "bet on the jockey"
Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson's, and other rare neurological disorders. Silo's mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.